News & Press Releases
Filter by:
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Of Counsel Michelle Capezza was quoted in a Fiduciary News article about the ERISA fiduciary framework for including private equity offerings in 401k plans. The article addresses the due diligence responsibilities plan sponsors must consider private equity gains traction as a plan diversification tool.
Mintz secured a rare trademark temporary restraining order (TRO) on behalf of IYO, Inc. against OpenAI, Sam Altman, Sir Jony Ive, and IO Products, Inc. The order temporarily bars the defendants from using the trademark associated with their new product launch.
